<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antihypertensive drugs and lipids</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antihypertensive drugs and lipids</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Antihypertensive drugs and lipids</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Bloch, MD, FACP, FASH, FSVM, FNLA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jan Basile, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Law, MD, FACP</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 01, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Drug-induced changes in lipid levels may be particularly important in hypertensive patients since up to 45 percent of untreated patients with primary hypertension (formerly called "essential" hypertension) already have lipid abnormalities, such as an elevated low-density lipoprotein (LDL) cholesterol [<a href="#rid1">1</a>]. In addition, genetic studies in humans suggest that a predisposition for the development of both hypertension and dyslipidemia may result from the inheritance of shared genetic risk factors [<a href="#rid2">2</a>].</p><p>In general, effects of blood pressure-lowering agents on lipid levels and effects of statins on blood pressure are modest. Blood pressure lowering and lipid lowering provide independent and additive reductions in cardiovascular risk [<a href="#rid3">3,4</a>] and may provide a high absolute benefit in individuals with multiple cardiovascular risk factors [<a href="#rid5">5</a>].</p><p>This topic will address the effects of antihypertensive medications on serum lipids and the effects of cholesterol lowering medications on blood pressure. The management of adults with hypertension, a review of established risk factors for cardiovascular disease, and cardiovascular disease risk assessment are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"</a> and  <a class="medical medical_review" href="/z/d/html/114029.html" rel="external">"Cardiovascular disease risk assessment for primary prevention: Risk calculators"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EFFECTS OF DIFFERENT ANTIHYPERTENSIVE AGENTS</span><span class="headingEndMark"> — </span>Treatment of hypertension can affect lipid levels. Some antihypertensive drugs, for example, have a neutral or beneficial effect on the lipid profile, while others have an adverse effect; such adverse effects are outweighed by the beneficial clinical effects of blood pressure lowering on cardiovascular risk.</p><p class="headingAnchor" id="H1959142449"><span class="h2">Antihypertensive drugs with adverse effects on plasma lipid levels</span><span class="headingEndMark"> — </span>Thiazide diuretics and beta blockers may adversely affect lipid levels. However, we would not avoid using these medications (if otherwise indicated) in a patient with dyslipidemia, and, similarly, we would not discontinue these medications in a patient just to improve the lipid profile [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H3"><span class="h3">Thiazide diuretics</span><span class="headingEndMark"> — </span>High doses of thiazide diuretics (50 to 100 mg of <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> or <a class="drug drug_general" data-topicid="9255" href="/z/d/drug information/9255.html" rel="external">chlorthalidone</a> in one study) produce an initial 5 to 10 percent elevation in total and low-density lipoprotein (LDL) cholesterol and a lesser increase in triglycerides [<a href="#rid7">7</a>]. The hyperlipidemic effect of thiazide diuretics is dose dependent [<a href="#rid7">7,8</a>]; contemporary doses lead to more modest lipid effects. As an example, there is little or no effect on lipid metabolism with hydrochlorothiazide 12.5 mg daily or its equivalent [<a href="#rid9">9</a>], a dose that may have an antihypertensive effect nearly as great as higher doses (see  <a class="medical medical_review" href="/z/d/html/3860.html" rel="external">"Use of thiazide diuretics in patients with primary (essential) hypertension"</a>). In addition, in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), chlorthalidone 25 mg produced a slightly higher mean total cholesterol than did <a class="drug drug_general" data-topicid="9565" href="/z/d/drug information/9565.html" rel="external">lisinopril</a> 40 mg or <a class="drug drug_general" data-topicid="8627" href="/z/d/drug information/8627.html" rel="external">amlodipine</a> 10 mg at four years, but the mean difference was &lt;2.5 mg/dL [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H4"><span class="h3">Beta blockers</span><span class="headingEndMark"> — </span>Beta blockers are a heterogeneous class of antihypertensive medications. The effect of beta blockers on serum lipids varies with their unique pharmacologic characteristics and may be more prominent among smokers [<a href="#rid8">8,11</a>].</p><p>Many traditional beta blockers, both cardioselective and noncardioselective (such as <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a>, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>, and <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>), lead to a fairly modest increase in triglycerides (20 to 40 percent), a decrease in high-density lipoprotein (HDL) cholesterol (approximately 10 percent), and little effect on total cholesterol or LDL cholesterol [<a href="#rid8">8,12</a>]. By contrast, <a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">labetalol</a> (a combined alpha and beta blocker) as well as beta blockers with intrinsic sympathomimetic activity (eg, <a class="drug drug_general" data-topicid="9233" href="/z/d/drug information/9233.html" rel="external">acebutolol</a> and <a class="drug drug_general" data-topicid="9774" href="/z/d/drug information/9774.html" rel="external">pindolol</a>) have relatively little impact on lipid levels due to a favorable effect on lipoprotein lipase [<a href="#rid8">8</a>].</p><p>Vasodilating beta blockers have a more favorable metabolic profile. <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">Carvedilol</a>, a combined nonselective beta and alpha-1 blocker, has less of a deleterious effect on triglyceride levels than <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> or <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> [<a href="#rid13">13,14</a>], and <a class="drug drug_general" data-topicid="9461" href="/z/d/drug information/9461.html" rel="external">nebivolol</a> appears to have a neutral effect [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'</a>.)</p><p class="headingAnchor" id="H3223229883"><span class="h2">Antihypertensive drugs with neutral or beneficial effects on plasma lipid levels</span><span class="headingEndMark"> — </span>Other than thiazide diuretics and beta blockers, antihypertensive medications generally have a neutral or beneficial effect on the lipid profile [<a href="#rid16">16</a>]. However, we do not consider these effects when choosing antihypertensive therapy.</p><p class="headingAnchor" id="H2632502254"><span class="h3">Angiotensin-converting enzyme inhibitors</span><span class="headingEndMark"> — </span>The angiotensin-converting enzyme (ACE) inhibitors appear to have no significant effect on plasma lipids [<a href="#rid8">8</a>] and may minimize or prevent the rise in lipids induced by diuretic therapy (via an unknown mechanism) [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H476496784"><span class="h3">Angiotensin receptor blockers</span><span class="headingEndMark"> — </span>In most clinical studies, angiotensin receptor blockers (ARBs) had either a neutral or modest beneficial effect on lipid levels [<a href="#rid18">18,19</a>].</p><p class="headingAnchor" id="H3969073543"><span class="h3">Calcium channel blockers</span><span class="headingEndMark"> — </span>The calcium channel blockers appear to have either a neutral or mildly beneficial effect on the lipid profile [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Alpha blockers</span><span class="headingEndMark"> — </span>The selective alpha-1 blockers, specifically <a class="drug drug_general" data-topicid="9806" href="/z/d/drug information/9806.html" rel="external">prazosin</a>, <a class="drug drug_general" data-topicid="9389" href="/z/d/drug information/9389.html" rel="external">doxazosin</a>, and <a class="drug drug_general" data-topicid="9975" href="/z/d/drug information/9975.html" rel="external">terazosin</a>, improve lipoprotein lipase activity and consistently demonstrate favorable effects on plasma lipids. These drugs lower total cholesterol by approximately 3 to 5 percent, reduce triglyceride levels by 3 to 4 percent, and mildly raise HDL cholesterol; the clinical significance of these changes is unclear [<a href="#rid8">8,20</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Sympathetic blockers</span><span class="headingEndMark"> — </span>The effect of the centrally acting sympathetic inhibitors, <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">methyldopa</a>, <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a>, and guanabenz, on the lipid profile has not been well studied. Both favorable and detrimental changes have been reported. On average, there is little, if any, change in lipid levels [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Effects of combination therapy</span><span class="headingEndMark"> — </span>The effect of combination therapy in most cases appears to reflect the sum of the effect of the individual drugs [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H515585183"><span class="h1">EFFECT OF STATINS ON BLOOD PRESSURE</span><span class="headingEndMark"> — </span>Treatment of dyslipidemia with statins may independently lower blood pressure, although the effect is modest [<a href="#rid21">21,22</a>]. This was demonstrated in the University of California San Diego (UCSD) Statin Effects Study, which randomly assigned 973 individuals to 20 mg of <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a>, 40 mg of <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">pravastatin</a>, or placebo [<a href="#rid23">23</a>]. At six months, both statins modestly reduced systolic and diastolic blood pressure by 2.2 and 2.4 mmHg, respectively.</p><p class="headingAnchor" id="H10"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of hypertension can affect lipid levels, and treatment of dyslipidemia with statins can affect blood pressure. In general, effects of blood pressure-lowering agents on lipid levels and effects of statins on blood pressure are modest. Blood pressure lowering and lipid lowering provide independent and additive reductions in cardiovascular risk. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thiazide diuretics (at doses higher than typically used) and some beta blockers (particularly <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a>, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>, and <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>) may adversely affect lipid levels. However, we would not avoid using these medications (if otherwise indicated) in a patient with dyslipidemia, and, similarly, we would not discontinue these medications in a patient just to improve the lipid profile. (See <a class="local">'Antihypertensive drugs with adverse effects on plasma lipid levels'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other than thiazide diuretics and beta blockers, most other antihypertensive medications generally have a neutral or beneficial effect on the lipid profile. However, we do not consider these effects when choosing antihypertensive therapy. (See <a class="local">'Antihypertensive drugs with neutral or beneficial effects on plasma lipid levels'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of dyslipidemia with statins may independently lower blood pressure, although the effect is modest. (See <a class="local">'Effect of statins on blood pressure'</a> above.)</p><p></p><p class="headingAnchor" id="H3935308247"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Norman M Kaplan, MD, now deceased, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Egan BM, Li J, Qanungo S, Wolfman TE. Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010. Circulation 2013; 128:29.</a></li><li><a class="nounderline abstract_t">Williams RR, Hunt SC, Hopkins PN, et al. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA 1988; 259:3579.</a></li><li><a class="nounderline abstract_t">Sever P, Dahlöf B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27:2982.</a></li><li><a class="nounderline abstract_t">Yusuf S, Lonn E, Pais P, et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med 2016; 374:2032.</a></li><li><a class="nounderline abstract_t">Williams B, Masi S, Wolf J, Schmieder RE. Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension. Cardiol Ther 2020; 9:19.</a></li><li><a class="nounderline abstract_t">Mänttäri M, Tenkanen L, Manninen V, et al. Antihypertensive therapy in dyslipidemic men. Effects on coronary heart disease incidence and total mortality. Hypertension 1995; 25:47.</a></li><li><a class="nounderline abstract_t">Grimm RH Jr, Leon AS, Hunninghake DB, et al. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med 1981; 94:7.</a></li><li><a class="nounderline abstract_t">Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133.</a></li><li><a class="nounderline abstract_t">Reaven GM, Clinkingbeard C, Jeppesen J, et al. Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 1995; 8:461.</a></li><li><a class="nounderline abstract_t">ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.</a></li><li><a class="nounderline abstract_t">Vyssoulis GP, Karpanou EA, Pitsavos CE, et al. Dyslipidemic effects of cigarette smoking on beta-blocker-induced serum lipid changes in systemic hypertension. Am J Cardiol 1991; 67:987.</a></li><li><a class="nounderline abstract_t">Wolinsky H. The effects of beta-adrenergic blocking agents on blood lipid levels. Clin Cardiol 1987; 10:561.</a></li><li><a class="nounderline abstract_t">Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126:955.</a></li><li><a class="nounderline abstract_t">Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227.</a></li><li><a class="nounderline abstract_t">Rizos E, Bairaktari E, Kostoula A, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003; 8:127.</a></li><li><a class="nounderline abstract_t">Kannel WB, Carter BL. Initial drug therapy for hypertensive patients with hyperlipidemia. Am Heart J 1989; 118:1012.</a></li><li><a class="nounderline abstract_t">Weinberger MH. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 1983; 5:III132.</a></li><li><a class="nounderline abstract_t">Derosa G, Ragonesi PD, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27:457.</a></li><li><a class="nounderline abstract_t">Kirk JK. Angiotensin-II receptor antagonists: their place in therapy. Am Fam Physician 1999; 59:3140.</a></li><li><a class="nounderline abstract_t">Levy D, Walmsley P, Levenstein M. Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Heart J 1996; 131:966.</a></li><li><a class="nounderline abstract_t">Spósito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83:1497.</a></li><li><a class="nounderline abstract_t">Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30:980.</a></li><li><a class="nounderline abstract_t">Golomb BA, Dimsdale JE, White HL, et al. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med 2008; 168:721.</a></li></ol></div><div id="topicVersionRevision">Topic 3867 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23817481" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3373705" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17145722" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27039945" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31933276" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7843752" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antihypertensive therapy in dyslipidemic men. Effects on coronary heart disease incidence and total mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7447225" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7992988" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effects of antihypertensive therapy on serum lipids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7662221" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12479763" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1673284" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Dyslipidemic effects of cigarette smoking on beta-blocker-induced serum lipid changes in systemic hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2889552" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The effects of beta-adrenergic blocking agents on blood lipid levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9182472" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15536109" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12808486" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2573262" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Initial drug therapy for hypertensive patients with hyperlipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6313523" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302981" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10392595" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Angiotensin-II receptor antagonists: their place in therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8615318" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10335771" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11114960" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413554" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
